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ABSTRACT  We used a library of 31  monoclonal and six polyclonal antibodies to compare the 
structures of the two  classes of cytoplasmic  myosin  isozymes  isolated  from  Acanthamoeba: 
myosin-I,  a  150,000-mol-wt,  globular  molecule;  and  myosin-II,  a 400,000-mol-wt  molecule 
with two heads and a 90-nm tail. This analysis confirms that myosin-I and -II are unique gene 
products and  provides the first  evidence that these  isozymes  have  at  least one structurally 
homologous region functionally  important for myosin's role in contractility. Characterization 
of the 23 myosin-II monoclonal antibody binding sites by antibody staining of one-dimensional 
peptide  maps and solid  phase, competitive  binding assays demonstrate that they bind to at 
least  15 unique sites on the myosin-II  heavy chain. The antibodies can  be grouped  into six 
families,  whose members  bind close to one another. None of the monoclonal antibodies bind 
to myosin-II light chains and polyclonal antibodies against myosin-II light or heavy chain bind 
only to myosin-II light or heavy chains,  respectively:  no antibody binds both heavy and light 
chains.  Six of eight monoclonal antibodies and one of two polyclonal sera that react with the 
myosin-I  heavy  chain  also  bind  to  determinants  on  the  myosin-II  heavy  chain.  The cross- 
reactive  monoclonal  antibodies  bind  to  the  region  of  myosin-II  recognized  by the  largest 
family  of  myosin-II  monoclonal  antibodies.  In  the two  papers  that  immediately  follow,  we 
show that this family of monoclonal antibodies to myosin-II  binds to the myosin-II tail  near 
the junction  with  the  heads  and  inhibits  both  the  actin-activated  ATPase of myosin-II  and 
contraction of gelled  cytoplasmic extracts  of Acanthamoeba cytoplasm. Further,  this structur- 
ally homologous region may play a key role in energy transduction by cytoplasmic myosins. 
Myosins from a  variety of nonmuscle  sources  share  many 
properties with  muscle  myosin  (10,  34),  yet  there  is  little 
evidence regarding their physiological functions or the mech- 
anisms by which  they transduce  chemical energy into  me- 
chanical force. We have taken an immunochemical approach 
to study myosin function and have produced polyclonal and 
monoclonal antibodies as probes for the structure and func- 
tion of the myosin isozymes in Acanthamoeba. 
Acanthamoeba  is  particularly  favorable  for  such  studies 
because  this  protozoa  has,  in  addition  to  a  conventional 
myosin called  myosin-II (31,  39),  unique  globular  myosin 
isozymes called myosin-I (37, 38; see reference 28 for review). 
Both classes of myosin bind to actin filaments and have Mg  ÷+- 
ATPase activity stimulated by actin (6,  7,  30,  38),  but they 
have distinctive physical and chemical properties. For exam- 
ple, the constituent polypeptides all have different molecular 
weights and one-dimensional peptide maps (13), and myosin- 
II has 32 cysteines (39) compared with none in myosin-I (37). 
Myosin-II (31,  39), like most conventional myosins, consists 
of two heavy chains and four light chains and has a molecular 
weight of 400,000 (39). There are two heads and a 90-nm tail 
that can aggregate laterally to form the backbone of bipolar 
filaments (35).  Myosin IA and IB have molecular weights of 
-150,000  and  consist  of a  single  heavy chain  plus  one  or 
more light chains (37, 38). Finally, rabbit polyclonal antibod- 
ies recognize unique  determinants on myosin-I and -II (12, 
33). The precise relationship between these myosins and their 
roles in cell motility remain to be established. 
In this paper, we elucidate the structural relationships be- 
tween myosin-I and -II through the production, purification, 
and immunological and physical characterization of 31 mon- 
oclonal and six polyclonal antibodies that bind specifically to 
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sional  peptide  maps  of myosin-II and  competitive  binding 
assays to intact myosin-II established that the 23 anti-myosin- 
II monoclonal antibodies bind at least 15 unique sites on the 
myosin-II  heavy  chain  that  are  clustered  spatially  into  six 
groups that we call families. We confirm that myosin-I and - 
II are the products of distinct myosin genes through studies 
of antibody  cross-reactivity:  none  of the  myosin-II  mono- 
clonal antibodies bind to myosin-I and two of the antimyosin- 
I monoclonals fail to cross-react with myosin-II. In addition, 
none of the antibodies recognize polypeptides larger than the 
175,000-mol-wt, myosin-II heavy chain. This data shows that 
myosin-I and -II each contain unique antigenic determinants 
and  their  heavy  chains are  not  produced  from  a  common 
high molecular weight precursor. In addition, we demonstrate 
for  the  first  time  that  these  two  morphologically  distinct 
myosin isozymes are, to some extent, structurally related: two 
monoclonals against myosin-I bind strongly to myosin-II and 
four others bind weakly. One of two polyclonal sera raised 
against purified myosin-I heavy chains also react with myosin- 
II.  The  most  cross  reactive  myosin-I  antibodies  bind  to  a 
constellation ofmyosin-II peptides identical to the set stained 
by the major family of myosin-II antibodies.  This family of 
antibodies binds to the proximal  end of the myosin-II tail, 
near its junction with the globular heads (23).  These studies 
show for the first time that the globular myosin-I molecule 
has domains structurally related to the filamentous myosin-II 
tail. 
In a second paper (23), we localize the binding sites of some 
of the monoclonal antibodies on  myosin-II by electron mi- 
croscopy of individual  myosin-II  molecules  and  myosin-II 
filaments and  evaluate antibody effects on  the assembly  of 
myosin-II filaments. We use the electron microscope data in 
conjunction with the relationships ascertained by competitive 
binding  studies  and  antibody  staining  of one-dimensional 
peptide maps to localize the binding sites of all but six myosin- 
II antibodies.  The electron microscopy also extends our un- 
derstanding of the relationship between some of the antibodies 
and  demonstrates  that  certain  antibodies  that  bind  to  the 
myosin-II  tail  are  potent  inhibitors  of  myosin-II  filament 
formation. 
In a third paper (25), we evaluate the effect of the antibodies 
on the actin activated ATPase activity of purified myosin-II 
and the contraction of gelled extracts of amoeba cytoplasm. 
Some  of  the  antibodies  inhibit  mechanochemical  energy 
transduction and confirm a role for myosin-II in the contrac- 
tion of a  cell  free model system.  The results from the three 
papers identify some parts of myosin-II that contribute to its 
major functions. Most of the conclusions agree with accepted 
ideas about the function of myosin but some are completely 
unpredicted. These features might relate to the special func- 
tional  requirements of contractility  in  nonmuscle cells  but 
could  be  general  properties  of myosin  that  have  not  been 
revealed by previous studies. 
Portions of this  work were  presented  at  Meetings  of the 
American Society for Cell Biology and the Biophysical Society 
(20-22,  33). 
MATERIALS  AND  METHODS 
Acanthamoeba  Cell Culture:  Acanthamoeba castellanii  were cul- 
tured  by the methods of Pollard and Koru (37), except that one half of the 
protease peptone in the culture medium was replaced by an equivalent weight 
of yeast extract (Difco Laboratories, Inc., Detroit, MI). 
Protein  Purification:  Acanthamoeba  myosin-I  was purified  by the 
method of Maruta  et al. (30) and myosin-II  was purified by the  method of 
Pollard et al. (39). 
Protein  Concentrations:  Protein  concentration  was measured  by 
absorbance at 280 nm. Extinction  coefficients were 0.56 cm2/mg for myosin- 
II and  1.4 cm2/mg for mouse lg. In some cases protein  concentrations  were 
estimated with the Bradford assay (3) or the Hartree assay (14), using ovalbumin 
as a standard. 
Monoclonal Antibody Production and Physical Characteri- 
za tion:  The production  and characterization  of monoclonal antibodies are 
described  in  detail  in  the  appendix.  The  specificity of each  antibody  was 
established by reaction with purified myosins, partial proteolytic and chemical 
digests of purified myosins, and whole cell extracts that were electrophoresed 
on polyacrylamide gels in the presence of  SDS, then transferred to nitrocellulose 
paper (43). Certain  physical properties  of each  antibody  and the  apparent 
affinity of each antibody for binding to myosin were determined  as detailed in 
the appendix. 
Rabbit Antibodies  to Myosin Subunits:  The heavy  and light 
chains  of purified  myosin-I  and  myosin-lI  were isolated  by preparative  gel 
electrophoresis  in  SDS  (40). Their purity  was established  by analytical  gel 
electrophoresis (36). Two rabbits were immunized with  15  to 50 t*g of each 
antigen  (myosin-I  heavy  chain,  myosin-If  heavy  chain  and  myosin-II  light 
chains) as described by Fujiwara and Pollard (11) and ~75  ml of blood was 
obtained  every other day during the second week after  boosting.  All of the 
rabbits produced specific binding. Gamma-globulins were obtained from serum 
by  ammonium sulfate  precipitation  (11)  and  were evaluated  by  the  same 
methods used for the monoclonal antibodies. 
Reaction of Antibodies with Polypeptides Separated by Gel 
Electrophoresis:  Polypeptides were resolved according to their molecular 
weight by SDS gel  electrophoresis  (36), then stained  with  antibodies  either 
directly (1, 4), or after electrophoretic transfer to nitrocellulose paper (43). To 
facilitate the transfer of  polypeptides, we added 0.1% SDS to the transfer buffer. 
After transfer, peripheral  lanes with molecular  weight standards  and a  small 
fraction of the test sample were stained for protein with amido black (32). A 7 
cm wide central lane with the remainder  of the test sample was incubated  in 
STTAB'  buffer (150 mM NaCI,  10 mM Tris-C1, pH 7.7, 3 mM NAN3, 0.1% 
Triton X-100, 0.1% bovine  serum albumin) for ~15  rain,  then cut with a 
microtome knife into 40 strips, each of which displayed the entire spectrum of 
resolved polypeptides. Individual strips were incubated  with specific antibody 
in STTAB or in culture  medium with 0.1% Triton X-100 added.  They were 
incubated at 4"C with gentle agitation for 4-48 h. The strips were washed with 
three changes of STTAB and reacted with approximately  1-10 x  105 cpm/ml 
~zsi-goat antimouse F(ab')z antibody (for monoclonal  antibodies) or with ~251- 
Protein A (for rabbit antibodies) in STTAB at 4"C with gentle agitation for 3- 
24 h. After washing with three changes of STTAB, the strips were mounted on 
Whatman 3MM paper with double stick tape and dried for 15-30 rain under 
vacuum.  Autoradiograms  were made on Kodak  X-Omat AR X-ray film and 
processed in an X-Omat processor. Exposures ranged from 15 rain to 10 d. 
Competitive Binding Assays:  We used a competitive, solid-phase 
binding assay to evaluate the ability of each unlabeled monoclonal antibody to 
block the binding of directly labeled homologous and heterologous antibodies 
to native myosin-II. DEAE-purified antibodies were labeled in vitro with  ~251 
or biosynthetically  with  [3~S]methionine as described  in  the appendix.  The 
assay was similar to the solid-phase binding assay, except that test antibodies 
were directly labeled, so no second, labeled antimouse antibody was required. 
Wells containing  myosin-II were washed once  with STTAB, then incubated 
with 0.4-2.5  x  10  -9 M  ~251-1abeled antibody  (0.5-3  x  105 cpm/well)  in the 
presence of 10  J- to 104-fold molar excess of unlabeled  DEAE-purified mono- 
clonal antibody. Incubation  with labeled antibody in the absence of unlabeled 
antibody  provided a measure of labeled antibody  binding without competitor 
present.  Alternately, competitive  binding  was analyzed with biosynthetically 
labeled antibody. Wells were incubated with 35S-labeled antibody ( 1  - 10 x  10  -8 
M, 2 x  l04 cpm/well) in the presence of a 2- to 100-fold molar excess of cold 
antibody. After 1-2 h of  incubation,  wells were rapidly washed three times with 
STTAB and counted.  In the case of 35S-labeled antibodies, the proteins were 
solubilized with 50 ill of 2 N NaOH, the solution was neutralized with 50 t~l of 
2 N HC1, and 95 gl of  the mixture was counted in 8 ml of Beckman EP Ready 
Solv scintillation cocktail in a liquid scintillation spectrophotometer. 
Nonspecific binding  was determined  in three ways that yielded essentially 
identical values. Labeled, nonspecific, control antibody was incubated  in wells 
' Abbreviations used in this paper.  STTAB,  150 mM NaC1,  10 mM 
Tris-C1, pH 7.7, 3 mM NAN3, 0.1% Triton X- 100, 0.1% bovine serum 
albumin;  DME,  Dulbecco's  modified  Eagle's  medium;  FBS,  fetal 
bovine serum. 
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containing an antigen unrelated to myosin-II;  or (for ~25I-labeled  antibodies) 
labeled, specific antibody was incubated in the presence of 1-10 x  10a-fold 
excess of cold, homologous  antibody. Backgrounds  determined in these three 
ways were identical in almost all cases tested and were usually 0.5-1% of the 
total counts of specific antibody  bound in the absence of competing  antibody. 
In each experiment raw counts were adjusted by subtracting the background 
determined in one of these three ways. 
RESULTS 
Hybridomas Produce Antibodies Against Myosin- 
I and -II 
We have produced and partially characterized monoclonal 
antibodies  against  myosin-I and  -II. Initially,  we  identified 
hybridomas secreting antibodies directed against cytoplasmic 
myosins from Acanthamoeba with a solid-phase binding assay 
using native myosin-I or -II as test antigens. We selected and 
cloned  23  hybridomas  producing  antimyosin-II  and  eight 
producing antimyosin-I (see  appendix).  Each antibody pro- 
ducing cell line was named according to the eliciting antigen 
CMI." for myosin-I and "M2." for myosin-II) followed by a 
unique  integer  suffix  to  designate  individual  clones.  Thus 
antibodies M2.1  through M2.27 are antibodies to myosin-II 
secreted  by  distinct  clones.  The  production,  purity,  and  a 
number of the  physical properties  of each antibody are de- 
scribed in the appendix and are summarized in the appendix 
in  Table  III. Knowledge of these  properties  is  essential  for 
subsequent  design  of experiments  and  interpretation  of the 
binding and inhibition  studies described in later papers (23, 
25, 26). 
Specificity of Monoclonal Antibody Binding to 
Acanthamoeba Polypeptides 
The monoclonal antibodies against myosin-I and -II react 
specifically and exclusively with myosin heavy chains among 
all of the Acanthamoeba polypeptides resolved by gel electro- 
phoresis in SDS (Fig.  1). The M2 antibodies bind only to the 
175,000-mol-wt myosin heavy chain. All M 1 antibodies bind 
to the  125,000-130,000-mol-wt  myosin-I heavy chain.  The 
polyacrylamide gels used for these experiments do not resolve 
the  myosin-IA and  -IB heavy chains,  so  we  do  not  know 
whether  our antibodies  bind  to  one  or  both  myosin-I iso- 
zymes. The  myosin-I antibodies  occasionally stained  a  low 
molecular weight species (< 11,200) that co-migrated with the 
dye  front,  well  ahead  of the  myosin  light  chains.  Unlike 
antibody staining of the myosin heavy chains, staining of the 
material at the dye front was not reproducible and may have 
been due to proteolytic fragments of myosin generated during 
sample  preparation.  Some  of the  myosin-I antibodies  cross 
react with myosin-II heavy chain (Fig. 1 b). Similar results are 
obtained when purified myosin-I and -II are used instead of 
whole  amoeba extract.  These  experiments  demonstrate  the 
specificity of the  monoclonal antibodies  to the two myosin 
isozymes and that the two myosins have at least one common 
antigenic site that is considered in detail below. 
[vlonoclonal  Antibody Binding to Myosin- 
II Peptides 
Two monoclonal antibodies,  M2.17 and M2.18, bind un- 
ambiguously to the myosin-II head because each reacts with 
FIGURE  1  Antibody staining  of whole Acanthamoeba  castellanii  polypeptides separated  by  PAGE in  SDS and  transferred  to 
nitrocellulose paper.  (Strip P) Whole amoeba polypeptides stained  with amido black.  (Numbered strips) (a) Autoradiograms 
depicting the staining of Acanthamoeba  myosin heavy chains by antibodies to myosin-II (M2.x). (b) A different experiment shows 
staining of whole amoeba proteins  by  myosin-I  antibodies (Ml.x).  (Strips C)  Staining by a control antibody directed against 
chicken pectoralis myosin subfragment-1. All blot strips were stained with antibody in culture supernatant to which Triton X-100 
had been added to a final concentration of 0.1%. Indistinguishable  results were obtained when blots were stained with purified 
antibody in STTAB buffer.  Migration of myosin  heavy chains are marked with their respective  molecular weights  (175,000 for 
myosin-II,  130,000 for myosin-I). D marks the position of the dye front. Antibody binding at the dye front was not reproducible 
like the staining of the 125,000-130,000- and 175,000-mol-wt peptides (see text). 
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comprise the bulk of  the head and contain the amino terminus 
of the  myosin-II heavy chain  (5).  This 70,000-mol-wt frag- 
ment  also  contains  the  ATP  and  actin-binding  sites.  We 
observed identical peptide binding results when myosin-II  was 
cleaved into  70,000-  and  105,000-mol-wt peptides during a 
dephosphorylation  experiment  (Fig.  2).  All  the  antibodies 
bind to the intact heavy chains, also shown on these blots. 
The remaining 21  antibodies, including the two M1  anti- 
bodies that cross-react with myosin-II, bind to the  105,000- 
mol-wt tryptic fragment that includes the carboxy terminus 
of the  heavy chain  and  all  of the  myosin-lI tail.  Assuming 
that the myosin tail has the same mass per unit length (885 
mol wt/nm) as tropomyosin, another alpha-helical coiled coil, 
we estimate that 80,000 tool wt of heavy chain is required for 
the 90-nm tail of myosin-lI. Thus, the N-terminal 25,000 mol 
wt  of the  105,000-mol-wt  tryptic  fragment  is  part  of the 
myosin-I1 head and antibodies that bind the  105,000-mol-wt 
fragment may bind either the head or the tail. 
Reaction  of each  antibody  with  the  myosin-II peptides 
produced by more extensive hydrolysis by four other proteo- 
lytic agents establishes that the  library of monoclonal anti- 
bodies recognizes a wide variety of antigenic determinants on 
myosin-II. Chemical cleavage (NHeOH or CNBr) or partial 
proteolysis (V-8  protease or alpha chymotrypsin) generated 
numerous peptides that we separated by gel  electrophoresis 
and stained with each antibody to evaluate the relationship 
among the  antigenic  sites.  Fig.  3  and  Table I  illustrate the 
results  for  the  hydroxylamine  peptides.  Table  IV,  in  the 
appendix, summarizes the data for the other cleavages.) Be- 
cause the digests are incomplete, the antigenic determinants 
usually appear on a  variety of peptides that range in size up 
to the  175,000-mol-wt heavy chain.  For unknown  reasons, 
no  antibodies  reproducibly  stain  peptides  with  molecular 
weights < 11,000.  Using peptides generated by all five of the 
hydrolytic agents,  several autoradiogram exposures of each 
antibody stained map, and both peptide mobility and staining 
intensity,  we  verified  the  similarities  or  differences in  the 
antibody staining patterns in order to determine the relation- 
ship between  the  antigenic  sites recognized by each of the 
antibodies (summarized in Tables I and II and in the appendix 
in Table IV). As described below, we grouped the antibodies 
into families delineated by the proximity of their binding sites 
on the myosin-ll molecule. 
For each type of digest, several antibodies bind to unique 
sets of peptides. For example, antibodies M2.1,  -5, - 13, - 15, 
-16,  -19,  and  -20  each  bind  to  a  unique  constellation  of 
NH2OH peptides (Fig. 3 and Table I). The antigenic sites that 
these antibodies recognize must be separated from each other 
by at least one NH2OH cleavage site. 
Alternately, more than one antibody may bind to an iden- 
tical set of peptides. These antibodies bind to antigenic sites 
that are close to or identical with one another, so we refer to 
these antibodies  as  members of a  family. Between the  two 
extremes are antibodies that bind to antigenic sites found on 
common high molecular weight peptides, but different small 
peptides. The antigenic sites that these antibodies recognize 
are probably close to one another, but separated by cleavage 
sites. 
The largest and most clear cut family of antibodies includes 
M2.4,  -6, -7, and -26 and provides an excellent example of 
how  the  antibody  families  are  delineated  by  the  peptide 
mapping studies. The antigenic sites to which these antibodies 
bind must be very close together, because none  of the  five 
hydrolytic agents (Fig.  3,  Tables I, II, and, in the appendix, 
Table IV) used resolves them onto different peptides. These 
antibodies are also indistinguishable by competitive binding 
assays (see below). Because of the close relationship between 
their antigenic sites (they may be identical), we refer to these 
antibodies as members of a "core" family. Additional family 
FIGURE 2  Antibody stain- 
ing of 105,000 and 70,000- 
mol-wt  fragments  of 
myosin-II  separated  by 
PAGE  in  SDS  and  trans- 
ferred to nitrocellulose pa- 
per. (Strip P) Amido black 
stained  peptides.  (Num- 
bered  strips)  Autoradi- 
ograms show staining of in- 
tact myosin-II heavy chain 
and the  105,000- and the 
75,000-mol-wt  fragments 
of myosin-II by antibodies 
to  myosin-II  (M2.x) and 
myosin-I  (Ml.x).  (Strip C) 
Staining by a control  anti- 
body  directed  against 
chicken  pectoralis myosin 
subfragment-1. 
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Antibody Staining of NHeOH Peptide Maps 
a.  Antibody staining of NH2OH peptides 
Antibodies with identi- 
Antibody  cal staining  Antibodies with related staining (differences) 
M2.- 
1  Unique 
2  4,6,7,10,21,26,27  22 (<32,000 mol wt) 27 (<29,000 mol wt) 
3  9 (<32,000 mol wt) 
4  4, 6, 7, 10, 21, 26  2, 27 (<29,000 mol wt) 22 (<32,000 mol 
wt) 
5  Unique 
6  4, 7, 10, 21, 26  2, 27 (<29,000 tool wt) 22 (<32,000 tool 
wt) 
7  4, 6, 10, 21, 26  2, 27 (<29,000 tool wt) 22 (<32,000 tool 
wt) 
8  Unique 
9  3 (<32,000 ml wt) 
10  4,6,7,21,26 
11  * 
12  * 
13  Unique 
15  Unique 
16  Unique 
17 
18 
19  Unique 
20  Unique 
21  4,6,7,10,26 
22 
26  4,6,7,10,21,26 
27 
2, 27 (<29,000 mol wt) 22 (<32,000 mol 
wt) 
18 (< 32,000 mol wt) 
17 (<32,000 mol wt) 
2, 27 (<29,000 mol wt) 22 (<32,000 tool 
wt) 
2, 4, 6, 7, 10, 21, 26, 27 (<32,000 mol wt) 
2, 27 (<29,000 tool wt) 22 (< 32,000  mol 
wt) 
2, 4, 6, 7, 10, 21, 26 (<29,000 mol wt) 
22 (<32,000 mol wt) 
b.  NH2OH families 









2, 22, and 27 
differ  slightly. 
13, 15, 20 
"11, 12 
Could be seen, but 
little  staining 
<60,000. 
* Staining pattern was nonexistent  or too restricted  to be properly  interpreted. 
members include antibodies M2.2, - 10, -21, -22, and -27 that 
bind  to  a  constellation  of peptides  that  is  similar,  but  not 
identical to the constellation stained by the "core" family. For 
example, antibody M2.27 stains the same alpha-chymotryptic 
and V-8 protease peptides as the core family (data not shown), 
but on NH2OH  (Fig.  3,  Table I) and CNBr maps (data not 
shown)  M2.27  stains  an  additional  26,000-mol-wt  peptide 
and an  11,000-mol-wt peptide, respectively, that are not rec- 
ognized by the core family. Antibody M2.27 stained peptides 
>29,000  mol wt on the NH2OH  map and >18,000  mol wt 
on the CNBr map in a  manner identical to staining by core 
family members, so one interpretation is that M2.27  recog- 
nizes an antigenic site on a  26,000-mol-wt  NH2OH  peptide 
that is generated from a  29,000-mol-wt  peptide by NH2OH 
hydrolysis  ~3,000  mol  wt  from  one  of its  ends.  Similarly, 
M2.27 recognizes an  11,000-mol-wt CNBr peptide that could 
result from cleavage at a methionine -7,000 mol wt from the 
end  of an  18,000-mol-wt  fragment.  Antibodies  of the  core 
family recognize no fragments smaller than the 29,000-  and 
18,000-mol-wt fragments, respectively. 
Competitive  Binding of Antibodies  to Myosin-II 
Competitive binding experiments between each 125I-labeled 
monoclonal antibody  and  a  large  excess  of each  unlabeled 
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monoclonal antibody provide independent evidence at higher 
resolution than peptide mapping for the relative positions of 
the  monoclonal antibody  binding  sites  on  myosin-II  sum- 
marized in (Fig. 4). 
Of the  21  antibodies  tested,  12  bind  to  unique  sites  on 
myosin-II; only an excess of homologous unlabeled antibody 
blocks the binding of labeled antibodies M2.1, -2, -5, -9, -12, 
-15,  -16,  -17,  -18,  -19,  -22,  and  -27.  The  binding  of the 
remaining nine antibodies is blocked by one or more unla- 
beled  heterologous antibodies.  In all  five cases tested,  Scat- 
chard plots show that the unlabeled heterologous antibodies 
reduce the apparent affinity of the labeled antibody without 
influencing the  stoichiometry of binding  (see  Fig.  7).  Thus 
they are competitive inhibitors of antibody binding. 
There are three families of antibodies by competitive bind- 
ing criteria:  M2.3  and -8; M2.4,  -6, -7, and -26; and M2.13 
and -20. The binding site of M2.10, while close to the binding 
sites of M2.4,  -6, -7, and -26 by antibody binding of peptide 
maps, must be slightly different,  because it does not inhibit 
binding  of the  other members  of its  family  as well  as  the 
members of the core family. This is confirmed by the reactions 
of the  antibodies with  alpha-chymotryptic peptides:  M2.10 
binds to a slightly different constellation of peptides than the 
antibodies in the core family (data not shown). FIGURE 3  Antibody staining of myosin-II peptides produced  by cleavage with hydroxylamine, separated  by PAGE in SDS and 
transferred  to nitrocellulose paper.  (Strip S) Molecular weight standards (X 10  -3, left). (Strip P) Peptides stained with amido black. 
(Strips 1-27) Incubated with specific monoclonal antibodies M2.1-M2.27 and bound antibodies localized by reaction with 1251- 
labeled goat antimouse F(ab')2 and autoradiography. 
TABLE II 
Summary of Families  of Antigenic Sites by Competitive  Binding 
and Peptide Staining 
Adjacent sites by com-  Additional adjacent sites 
Family  petitive binding  by peptide staining 
A  1,11 
B  4, 6, 7, 10, 26  21, 27>22 >2 
C  3,8  9,12 
D  5, 16, 19 
E  13, 20  15 
F  17, 18 
Two of the antibody families delineated by these competi- 
tive binding studies are subsets of  those revealed by the peptide 
map staining studies.  The competitive binding studies dem- 
onstrate a  close relationship between antibody M2.3  and -8 
that  was  not  observed  by  peptide  mapping.  This  may  be 
because M2.8  stained  the  NH2OH generated peptide  maps 
only poorly and failed to stain the CNBr, alpha-chymotryptic 
and V-8 protease maps in an interpretable fashion (see Table 
IV).  In  general,  the  competitive  binding  approach  distin- 
guishes  differences  in  antibody  binding  sites  with  greater 
resolution than the one-dimensional peptide maps. 
A  number of unlabeled antibodies appear to enhance the 
binding  of the  ~2SI-labeled antibodies.  For  example,  M2.3 
more than doubles the amount of ~25I-labeled M2.12 bound 
to the solid-phase assay. These two antibodies bind close to 
one another on the tail of myosin-lI (23).  In addition,  most 
of the members of the family that includes M2.2, -4, -6, -7, 
etc., enhance the binding of M2.5. These observations suggest 
that the mechanism of enhanced binding of labeled antibody 
may be caused  by specific changes  in  the  structure  of the 
myosin molecule induced by the binding of unlabeled anti- 
body. A less likely explanation is that increased binding may 
result from potentiated binding of myosin antigen to the solid- 
phase substrate throughout the incubations and washes of the 
binding assay. 
Myosin-I and -II Share  Antigenic Determinants 
Certain  myosin-I antibodies  bind  both  to  myosin-I and 
myosin-II heavy chain (Fig.  1). To examine this cross reactiv- 
ity  more  closely,  we  stained  myosin-II peptide  maps with 
myosin-I antibodies and evaluated the ability of high concen- 
trations of unlabeled myosin-I antibodies to block the binding 
of ~25I-labeled M2 antibodies to intact myosin-II. Antibodies 
M 1.3 and M1.4 stain myosin-II peptides generated by four of 
the five hydrolytic methods described above (Fig. 5 shows the 
data for the V-8 protease peptide maps). On each map these 
M1 antibodies stained a constellation of peptides identical to 
those that the major family of M2 antibodies recognized. In 
addition MI.4 inhibited the binding of 12SI-labeled M2 anti- 
bodies from core family that includes M2.4,  -6,  -7, and -26 
(Fig. 4). Therefore M1.3 and MI.4 bind to sites on myosin-II 
that are close to one another and that must be structurally 
related to antigenic determinants found on myosin-I. Subse- 
quent electron microscope localization studies show that this 
major family of M2  antibodies  binds to  a  domain  on  the 
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I-LABELED  M2.X  ANTIBODY 
1  2  3  4  5  6  7  8  9  10  12  15  16  17 
1  0  ~  ~  ~  ~  ~o~,  ~o~  ,o~  ~  ,~]  ~  ,o~  ~  ~ 
2  77  O  90  88  182  98  1] 3  ]19  94  96  75  44  94  70 
121  104  O  70  123  92  99  0  95  104  240  94  92  118 
I 
4  ]26  69  I01  0  152  O  O  115  i00  O  57  37  99  90 
k]]7  98  94  98  0  105  10"3  i]0  94  107  -  74  59  94  I17 
6  ;118  7l  95  0  153  0  O  100  i01  1  127  96  97  78 
71  5g  99  O  130  0  O  115  96  O  145  98  118  95 
~  94  102  71  101  94  99  107  O  102  lOl  107  95  lOl  118 
~_~  1(  89  64  1oi  8  1~s  2~  10  i[8  98  O  60  99  85  104  75 
~  ~  12  81  85  I09  69  140  97  i00  I02  I04  97  O  74  84  t12  i03 
,~  13  8~  103  96  65  128  98  97  I~2  96  9~  63  0  s6  lo2  io6 
15  63  SO  97  61  129  95  96  101  I00  99  60  92  O  93  96 
16  75  60  92  33  102  69  42  Iii  96  72  74  86  58  O  97 
17  51  64  90  75  143  99  97  173  96  101  72  106  75  103  0 
18  102  70  10l  67  !19  97  92  96  97  99  65  92  79  106  307 
20  91  98  101  53  121  87  95  84  98  94  51  O  98  I00  109 
22  96  60  97  57  12~  87  100  85  98  90  57  74  74  109  107 
26  78  84  78  1  104  3  1  32  9s  0  43  95  85  105  87 
27  67  61  99  39  142  81  78  I00  96  93  51  I00  72  110  70 
11  88  g7  88  60  149  I00  97  i01  96  109  67  86  76  106  89 
19  102  135  103  70  111  I00  100  89  102  I11  86  79  144  90  126 
C  i00  I00  i00  I00  I00  i00  i00  I00  I00  I00  I00  I00  I00  100  I00 
M1.4  75  89  99  4  92  16  5  89  lOl  }00  67  107  95  Ii0  94 
18  20  22  26  27 
1~9  120  99  88  91 
80  I18  77  96  94 
138  93  92  84  93 
Ii0  91  61  O  90 
125  113  98  85  102 
I00  94  73  0  89 
120  II0  72  0  90 
86  78  49  132  96 
115  135  89  93  96 
97  122  98  2  98 
114  71  86  99  96 
I00  O  75  I01  102 
92  92  90  86  106 
90  102  87  34  94 
105  136  88  84  99 
0  93  86  o7  94 
90  0  99  97  97 
84  94  0  73  97 
93  112  63  O  98 
77  128  i05  75  0 
101  110  98  82  102 
119  105  97  102  102 
100  100  100  [00  100 
100  116  198  2  92 
FIGURE 4  Summary of  competitive  binding experiments.  1251-labeled antibodies are  numbered  across the  top. Unlabeled, 
competing antibodies are numbered on the left side. The values in the matrix are the percent of control binding by 12Sl-labeled 
antibody in the  presence of  103-104 excess of  unlabeled homologous (on the  diagonal) or  heterologous antibodies. Control 
binding was established by incubating labeled antibody in the absence of unlabeled antibody. Bold face numbers highlight the 
cases where binding of labeled antibodies was inhibited by 90% or more. 
myosin-II tail near its junction with the heads. These experi- 
ments and functional  studies  show that these antibodies are 
potent  inhibitors  of myosin  ATPase  activity  and can  block 
contraction  of gelled  extracts  of Acanthamoeba  cytoplasm. 
"1008  THE  JOURNAL OF  CELL BIOLOGY - VOLUME 99, 1984 
Together these studies demonstrate that myosin-I shares some 
limited structural  homology with a domain in the myosin-II 
tail  that  is essential  for actin-activated  ATPase  activity and 
gel contraction. also cross-reacts with myosin-II heavy chain. Rabbit myosin- 
II light chain antibodies react exclusively with myosin-II light 
chains: no cross-reactivity with either myosin heavy chain or 
myosin-I light chains was observed. The rabbit antibodies to 
the myosin-II heavy chains compete poorly with most of the 
~25I-labeled monoclonal antibodies to myosin-II for binding 
to  myosin-II.  The  exception is  that  sera  from  one  of the 
rabbits  immunized  with  myosin-II  heavy  chain  (AM-2) 
strongly inhibits the binding of M2.8 to myosin-II (data not 
shown). 
DISCUSSION 
Myosin-I and -II Are Different  Gene  Products 
Myosin-I and -II are likely the products of distinct genes. 
All  of the  antibodies  against  myosin-II  and  some  of the 
antibodies against myosin-I recognize antigenic determinants 
found specifically on the myosin isozyme against which they 
were raised. Therefore, each myosin has major domains that 
are antigenically and, therefore, structurally unique. None of 
the antibodies recognize polypeptides with higher molecular 
weight than the myosin-II heavy chain. Thus, putative higher 
FIGURE  5  Monoclonal antibody staining of myosin-II peptides gen- 
erated  by digestion with V-8 protease (S. aureus)  and separated  by 
gel  electrophoresis  demonstrates  immunological  cross  reactivity 
between myosin-I and -II. Molecular weight standards (X 10  -3) are 
on  the  left.  (Lane  P)  Amido  black  stained  peptides.  (Numbered 
lanes) Autoradiograms of one dimensional peptide  maps stained 
with antibodies to myosin-II (M2.x) and  myosin-I (Ml.x) (Lane C) 
Control monoclonal antibody to chicken pectoralis myosin subfrag- 
ment-1.  Two myosin-I antibodies (M1.3  and M1.4) react with the 
same  myosin-II  peptides  as  the  major  core  family  of  myosin-II 
antibody that includes M2.4, -6, -7, and -26. 
It is not clear why several M 1 antibodies that bound intact 
myosin-II heavy chain in whole cell extracts (Fig.  1) failed to 
recognize myosin-II peptides generated by various hydrolytic 
agents.  We  speculate  that  these  antibodies  may  have  had 
lower apparent affinities to binding sites on myosin-II or that 
such sites were destroyed during proteolysis. 
Comparative  Studies with Rabbit Antibodies  to 
Acanthamoeba  Myosins 
Antibodies produced by rabbits immunized with electro- 
phoretically purified myosin-I heavy chains,  myosin-II light 
chains  or  myosin-II heavy chains  confirm and  extend the 
conclusions drawn  from the experiments with  monoclonal 
antibodies. Solid-phase antibody binding assays with purified 
myosins (see Table V) and antibody staining of myosin poly- 
peptides separated by gel electrophoresis (Fig. 6) establish the 
specificity of the  polyclonal antibodies.  Antibodies  to  the 
myosin-II heavy chain or light chains react exclusively with 
myosin-II heavy or light chain, respectively, whether purified 
myosin-II or whole cell extract is used as test antigen in gel 
overlay experiments. Both rabbits immunized with myosin-I 
heavy chains produced antibodies that react with the heavy 
chains of myosin-I and  one of the antimyosin-I antibodies 
FIGURE 6  Polyclonal antibody overlay of myosin-I and -II peptides 
separated  by gel electrophoresis. (a) Coomassie  Blue-stained gels 
indicated polypeptide composition of purified myosin-I (I) and -II 
(11) (b-e) Autoradiograms of gels incubated with different antibodies 
and  bound  antibodies localized with 12Sl protein  A.  (b)  JH-6,  an 
immune  serum  directed  against  myosin-I,  stains  myosin-I  heavy 
chain and not myosin-II heavy chain. (c) JH-7, a sera from a rabbit 
also  immunized with myosin-I  heavy chain, stains  both  myosin-I 
and -II heavy chains. (d and e) AM-2 and AM-3, immune sera from 
rabbits immunized with electrophoretically purified myosin-II heavy 
chains and light chains respectively. They stain only their respective 
antigens. 
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present  only  briefly  or  in  very  low  concentration.  Taken 
together, these observations provide strong evidence that the 
two classes of myosin isozymes from Acanthamoeba  are the 
products of distinct genes. Our observations with monoclonal 
antibodies therefore confirm the polyclonal immunochemical 
studies (12, 33) and peptide mapping experiments (13) on the 
two classes of myosin (12,  33). Further, they concur with the 
observations that myosin-I is not generated from myosin-II 
during purification. 
Myosin-I Shares an Antibody Binding Site 
Located on the Myosin-II Tail 
Although  myosin-I and  -II are clearly distinct  they have 
some structural homology. Two monoclonal antibodies (M 1.3 
and M 1.4) and one polyclonal (JH-7) serum bind tightly to 
antigenic determinants on the heavy chains of both myosin-I 
and -II. By both competitive binding and peptide mapping 
the two cross-reactive M 1 antibodies bind to the same region 
of the myosin-II heavy chain as M2.4,  -6, -7, and -26.  This 
family of M2 antibodies binds to sites on the myosin-II tail 
near its junction with the heads (23).  Thus, these common 
antigenic sites are unlikely to be either the actin-binding sites 
or  the  catalytic  sites  of the  two  myosins.  This  is  the  first 
evidence  that  myosin-I may  have  a  short  tail.  This  is  an 
unexpected finding, because the tail of myosin-II is presum- 
ably  a  helical  coil  composed  of two  parallel  polypeptide 
chains, making it unclear how myosin-I with a  single  heavy 
chain could form such a structure. 
This  structurally  homologous region  of the  myosin  iso- 
zymes appears to be important for myosin function in vitro, 
and probably in vivo, because the M2 antibodies that bind to 
this  region  inhibit  both the  actomyosin-II ATPase  activity 
and the contraction of gelled extracts of amoeba cytoplasm 
(25).  The  fact  that  myosin-I shares  a  homologous  region 
suggests that this region may be fundamentally important for 
the function of both myosin isozymes. 
Characteristics  of the Antigenic Sites 
All of the antimyosin monoclonal antibodies and at least 
some of the antibodies in the polyclonal sera bind to myosin 
in solid-phase binding assays and to myosin heavy chains that 
were SDS denatured and transferred to nitrocellulose paper. 
In the solid-phase binding assay, the myosin probably retains 
at  least part  of its  native  structure,  but  it  is  unlikely that 
significant renaturation of the SDS denatured myosin takes 
place on  the  nitrocellulose.  It is therefore possible that  the 
antibodies recognize the  primary sequence at the  antigenic 
site in both its native and denatured form. We conclude that 
the three-dimensional structure of the antigenic determinant 
is probably not important for antibody binding, but we have 
not critically compared the relative apparent affinities of the 
antibodies for native versus denatured myosin. 
The 23 monoclonal antibodies directed against myosin-II 
recognize at least  15  unique  antigenic determinants on the 
myosin-II  heavy chain. They can be grouped into core families 
of antibodies whose members competitively inhibit each oth- 
er's binding to myosin-II. Associated with these core families 
are other family members that stain one-dimensional maps 
of the myosin-II heavy chain in a pattern similar or identical 
to that of the core family (Table II). In a following paper (23), 
we use electron microscopy in conjunction with the relation- 
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ships established  here to  localize directly all  but  six  of the 
antibody binding sites on the myosin-II molecule. 
Origin of Cells That Secrete Antibodies to 
Common  Antigenic Sites 
The relationship between antibodies within core families is 
fascinating. It is likely that the antibodies we have character- 
ized  are  the  result  of unique  fusion  events  because  each 
secreting cell line comes from a different culture well plated 
with hybridoma fusion products and, in addition, the hybri- 
doma colonies are physically separated into individual culture 
plates during cloning. However, it is possible that more than 
one fusion might have occurred between myeloma cells and 
B-lymphocytes that came from the same clone in the immu- 
nized mouse.  Consider the core family that includes  M2.4, 
-6,  -7,  and  -26.  Three  of the  antibodies  are  of the  IgG2a 
isotype. M2.26 is an IgGj. Antibodies M2.4,  -6, and -7 may 
be secreted by monoclonal hybridomas that were the  result 
of fusions between parent myeloma cells  and  identical but 
distinct B-lymphocytes that were clonally related to one an- 
other.  Such  B-lymphocytes could  have been  sister progeny 
derived during maturation of the immune response to a single 
antigen  recognition  event in  the  mouse.  Because immuno- 
globulin  class switching during  maturation  of the  immune 
response can give rise to closely related B-iymphocytes secret- 
ing antibodies of different immunoglobulin isotypes directed 
against identical antigenic sites (42),  it is even possible that 
M2.26  share some common lineage with other members of 
the core family. 
Alternatively, the members of the core family may recog- 
nize unique antigenic determinants that are so close to one 
another that the differences between them remain unresolved 
by our techniques. Under such circumstances, each antibody 
would be the result of a  unique antigen recognition event in 
the mouse. Subtle differences in the functional effects of these 
antibodies on actomyosin-II ATPase activity (25) suggest that 
this interpretation  may be correct. The extent of inhibition 
by antibodies M2.4, -6, -7, and -26 are all subtly different. 
APPENDIX 
This appendix is divided into two parts. First, we detail antibody production 
and characterization.  Second, we supply supporting  data that provides guide- 
lines for reproducing these experiments and supplies important but not essential 
data for interpreting the experiments discussed in the text. 
Antibody Production and Characterization 
IMMUNIZATION:  5-10-wk-old female C57B6 mice, obtained from Jack- 
son Labs (Bar Harbor,  ME), were immunized and boosted  as described by 
Strand (41) with purified native proteins (-20 ~g of myosin-I and -200 ~g of 
myosin-ll) in 0.15 M NaCI buffered with  10 mM sodium phosphate (pH 7.5) 
or 10 mM imidazole-Cl (pH 7.0). Protein solutions were mixed with an equal 
volume of Freund's complete adjuvant for the primary immunization  and with 
Freund's incomplete adjuvant  for all but the last boost. Between days 24 and 
40, blood  was obtained  from the  tail  vein and tested for antibodies  against 
myosin  by  the  solid-phase  binding  assay  described  below.  The  assay  was 
considered positive when dilutions  of one part in 104 to 105 were higher than 
background  binding.  Positive mice were given a  final, intraperitoneal  boost 
with antigen in buffered saline (no adjuvant). 
FUSION AND HYBRIDOMA CULTURE:  Mice  were cervically dislocated 
3-4 d following the final boost, their spleens were removed surgically, rinsed 
three times in Dulbecco's  modified Eagle's medium (DME), then dissociated 
mechanically into DME by maceration  through a stainless steel screen with a 
rubber policeman.  Subsequent steps were a modification of a fusion protocol 
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FIGURE  7  Competition  between  ~2Sl-labeled  monoclonal  antibodies  and  unlabeled  antibodies  for  binding  to  myosin-II.  (a) 
Competition between M2.3,  M2.6,  and M2.13  and a  panel of monoclonal antibodies to myosin-II  (M2.x) and myosin-I (Ml.x). 
Binding is expressed as a fraction of ~2Sl-labeled antibody binding in the absence of unlabeled antibody. Homologous antibody 
plus one or more heterologous antibodies compete with  each antibody. (b) Scatchard plots of ~2Sl-labeled antibody binding in 
the presence of approximately equivalent amounts of unlabeled antibody demonstrate competitive inhibition  of binding.  12Sl- 
labeled antibody M2.4  alone (O);  binding of ~2Sl-labeled M2.4  in  the presence of approximately equimolar concentrations of 
unlabeled M2.10 (O) or M2.6 (A). The differences in the slopes show that M2.10 does not inhibit binding of M2.4 as well as M2.6. 
TABLE III 
Physical Properties of Monoclonal Antibodies to Acanthamoeba 
Myosins 
Apparent 
Antibody  Isotype  KCI  pl*  KD 
mM  nM 
M2.X 
1  IgG2^  52  6.0  10-15 
2  IgG1  86  6.0  30-50 
3  IgG2B  63  6.0  2-3 
4  IgG2a  42  7.2  10 
5  IgG2^  62  5.9  0.1 
6  IgG28  36  7.2  3 
7  IgG2B  --  --  -- 
8  IgM  --  --  4 
9  IgG1  33  7.2  16 
10  IgG~  28  7.0  4 
11  IgG1  52  6.4  5 
12  IgG D28  66  6.2  38 
13  IgG1  38  7.1  4 
15  IgG~  49  6.5  3 
16  IgM  --  --  6 
17  IgG1  73  6.6  7 
18  IgG2B  38  7.0  26 
19  IgG~  32  7.3  12 
20  IgG1  36  7.4  10 
21  IgG2^  --  --  -- 
22  IgG1  42  6.6  13 
26  IgG~  33  7.4  1 
27  IgG2B  48  7.2  5 
M1.X 
1  IgG2a  56  6.4  -- 
2  IgM  --  --  -- 
3  IgM  --  --  -- 
4  IgM  --  --  -- 
5  IgM  --  --  -- 
6  IgM  --  --  -- 
7  IgG2B  52  6.7  -- 
8  IgG1  48  6.8  -- 
* pl:  Isoelectric focusing of these proteins resulted in  four  to five  closely 
spaced Coomassie Blue-stained bands, a pattern typical for purified  mon- 
oclonal antibodies. The pl tabulated was the average pl for the bands. 
TABLE IV 
Families Defined  by Antibody Staining of Peptide Maps 
Alpha-chymo- 
tryptic families  V-8 Protease "families"  CNBr Families 
1,11  1  3,9 
2  2,4,6,7,10,21,26,  4,6,7,10,21,22, 
27*  26, 27 
9  5,19 
13,  15, 20  17 
3 
4, 6, 7, 21, 22, 
26, 27* 
9,12 





17  18 
18 
1,2,8,11,12,13, 
15,  16, 201 
3, 5, 8,  10,  12,  16,  191 
20 
* M2.22 stains myosin-II peptides >40,000 mol wt like the members of this 
family. 
* M2.10 stains myosin-II peptides >24,000  mol wt like the members of this 
family. 
s M2.20 stains myosin-II peptides >29,000 mol wt like the members of this 
family. 
I Staining pattern was too restricted to be interpreted. 
0.83% NH4CI. The remaining cells were pelleted through ice cold  100% fetal 
bovine serum (FBS), and washed once in DME. Cells of the parent  myeloma 
line (P3-X63-Ag8.653 [see reference  17]) were grown at low density (5-50 × 
104 cells/ml) for 4 d before fusion in 20% FBS, 80% DME containing  130 #M 
8-azaguanine  and then washed  three  times in DME  to completely  remove 
serum, which inhibits  cell fusion. Cells were mixed in a ratio  of 2:1  to  10:1 
spleen to myeloma cells and co-pelleted in a  50  ml conical centrifuge tube. 
Supernatant  was removed and the cells were gently dispersed by tapping the 
tube. Fusagen (l  ml of 25%  polyethylene glycol [PEG  1000], 15%  dimethyl 
sulfoxide in DME adjusted  to pH 7.4 with NaOH) was added dropwise over 
the course of l  min. After 30-60 s, 6 ml of DME were added dropwise over 
the course of  6 min. Slow addition of fusagen and diluents is required, probably 
to minimize  osmotic  shock. The cell suspension was mixed by intermittent, 
gentle swirling to maintain  homogeneity throughout the procedure. After a 3- 
min incubation,  the fusion reaction was inhibited by slow addition (10 ml in 2 
min) of 20%  FBS, 80%  DME.  Cells were pelleted, and the supernatant  was 
carefully removed. Cells were resuspended in HAT-hybfidoma growth medium 
consisting  of 70%  DME,  20%  FBS, 10%  Medium  NCTC  135  (a  growth 
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Solid Phase Binding Assays Reveal the Cross-reactivity of 
Polyclonal Rabbit Antibodies 
Antibody 
Antigen applied to well 
0.2 #g Myosin-I  0.2 tzg Myosin-II 
125j_pr  o_ 
rein A  12sl-Protein 
specific  A specific 
cpm  (Serum  cpm  (Serum 
bound*  dilution)  bound*  dilution) 
Antimyosin-I heavy chain 
Rabbit IH-6  11,600  (10  -z)  20  (10  -2) 
Rabbit JH-7  5,100  (10  -2)  4,100  (10  -2) 
Antimyosin-II heavy chain 
Rabbit AM-1  460  (10  -2)  299,000  (10  -3) 
Rabbit AM-2  230  (10  -2)  352,000  (10  -3) 
Antimyosin-II light chains 
Rabbit AM-3  580  (10  -2)  158,000  (10  -3) 
Rabbit AM-4  730  (10  -2)  103,000  (10  -3) 
Specific cpm, cpm with immune serum minus cpm with preimmune serum 
at the same dilution from the same rabbit. The preimmune cpm were in 
the range 500 to 2,000 cpm. 
supplement), to which glutamine  (2 mM), insulin (0.25 U/ml), pyruvate (450 
ttm), oxalacetic acid (l. l raM), and HAT (hypoxanthine,  100 ~tM, aminopterin, 
0.4 ttM, and thymidine, 20 tiM) were added. Sometimes penicillin (100 U/ml) 
and streptomycin (100 ttg/ml) were included, but fungicides were avoided. The 
postfusion cells were immediately plated into 24 well plates (3.5-ml wells) at a 
density of 1-10 x  l06 spleen cells/well in  1 ml of growth medium.  The wells 
were preplated with 0.5 ml of hybridoma growth medium containing -  10-100 
x  l0  s mouse peritoneal  macrophages  per well (9). Plates were incubated  at 
37"C in humidified air containing  5-8%  CO2. Cells were fed every 3-5 d by 
replacing 0.5 ml of culture supernatant in each well with fresh HAT hybridoma 
growth medium.  After 2-3 wk cells were weaned from HAT in an identical 
growth medium from which aminopterin  was omitted (HT-hybridoma  growth 
medium). In 2-3 wk, or as soon as growth was sufficient to turn one or more 
of the culture wells orange-yellow, cultures were assayed for antibody produc- 
tion with the solid-phase binding assay described below. Assays were repeated 
every 3-4 d for ~ l0 d after new wells failed to appear with growth. Wells were 
considered positive if counts were five times background.  Cells from positive 
wells were grown in HT-hybridoma  growth medium in flasks for freezing and 
cloning as soon as possible. 
CLONING AND FREEZING:  Cells  from positive cultures were cloned in 
0.33% agar (Bacto Agar, Difco Laboratories, Detroit, MI) in HT supplemented 
hybridoma growth medium over a basal layer of 0.5% agar (29). After growth 
in flasks, all of the lines producing antibodies to myosin-II and some producing 
antibodies to myosin-i were recloned, then frozen, and stored in liquid nitrogen. 
Hybridomas 0-4 x  106/ml) were frozen in 40% FBS, 50% DME, and 10% 
DMSO, or 90% FBS and 10% DMSO using 1 ml storage vials (Nunc, InterMed, 
Denmark).  An  immersion  cooler  (Cryocool; Neslab,  Portsmouth,  NH) con- 
trolled  the  rate  of the temperature  change: -3*C/min from 37"C to -10*C, 
then -  l*C/min to -70"C. Frozen cells were stored in liquid nitrogen. 
ANTIBODY PRODUCTION BY ASCITES TUMORS IN MICE:  Forlarge 
scale production  of antibodies, cloned, antibody producing cells were grown as 
ascites tumors in pristane primed C57B6-BALBC Fl mice (16). After 2-15 wk 
ascites fluid was collected by peritoneal tap. After removal of cells by centrifu- 
gation, antibodies  were precipitated  with an equal  volume  of saturated  am- 
monium sulfate (pH 7.0) containing  10 mM K+-EDTA and stored as a pellet 
at 4"C. 
EFFICACY  OF  MONOCLONAL  ANTIBODY TECHNIQUES:  Using 
these methods for producing monoclonal  antibodies, we found that myosin-II 
proved an excellent antigen:  two fusions yielded cells secreting antibody  to 
myosin-ll  in 200  out of 200  wells each  seeded with  106  spleen cells. Three 
myosin-I fusions yielded 29 positive wells out of 300 wells seeded. This lower 
success rate  may be  related  to  the  smaller  amounts of myosin-I  used  for 
immunization.  Cells from 23 of the wells producing  antimyosin-II  and from 
eight wells producing  antimyosin-I  were successfully cloned  in soft agar. All 
antimyosin-II  producing  clones  were  cloned  a  second  time  and  subclones 
produced  antimyosin-lI  that was of the same, single Ig isotype as the parent 
clone, so we conclude that the second cloning step was probably unnecessary. 
We verified that our antibodies were monoclonal by analyzing antibody labeled 
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biosynthetically in culture and antibody purified from ascites fluid by SDS gel 
electrophoresis and by isoelectric focusing. 
Supplemental Details for Experimental Protocols 
DEAE PURIFICATION  OF MONOCLONAL ANTIBODIES:  Antibodies 
were purified from the 50% ammonium sulfate pellets by DEAE chromatog- 
raphy by standard techniques except the ion exchange column was equilibrated 
with 20% sucrose. The sucrose kept IgGs in solution at concentrations in excess 
of 20 mg/ml even under low salt (5 mM Tris-Cl, pH 8.0) conditions.  Partial 
purification  of specific monoclonal  Igs from other serum proteins  and from 
contaminating  endogenous mouse Igs was greatly facilitated because the pro- 
teins were actually chromatographed,  rather than pooled in the flow through 
from the ion exchange column. Ammonium sulfate precipitates of ascites fluid 
were washed one to three times by pelleting and resuspension in 50% ammo- 
nium sulfate. Washed pellets were resuspended in a minimal volume of  column 
buffer, then dialyzed for at least 18 h against three changes of 500 vol of  column 
buffer. Samples of 1-10 ml contained  5-50 mg/ml protein  and were clarified 
by centrifugation for 15 min at 18,000 g then chromatographed  on the DEAE. 
After a two column volume  buffer wash, a 200-ml linear gradient of 0-300 
mM KC1 in column buffer was applied to elute the antibodies. The antimyosin 
activity eluted with the major peak of protein at a salt concentration  character- 
istic of the particular  antibody.  IgMs were purified by two to three cycles of 
precipitation in 5 mM Tris-C1, pH 8.0, and then dissolved in 150 mM NaCI, 5 
mM  Tris-Cl,  pH  8.0. SDS gel  profiles of the  chromatographed  antibodies 
establish their  purity and are shown in Fig. 8. The molecular  weights of the 
heavy and light chains of the IgGs vary somewhat but average ~50,000  and 
25,000 respectively. The two IgMs (M2.8 and  16) have 70,000-mol-wt heavy 
chains and 25,000-mol-wt light chains. Interestingly, antibody M2.5 is an IgG2^ 
by double diffusion analysis, and is soluble in low salt, but the heavy chains 
are about the same size as IgM on SDS gels. 
ISOELECTRIC FOCUSING:  Small samples of DEAL-purified antibody, 
~251-antibody, or 35S-antibody in culture supernatant were isoelectric focused in 
12 x  22 x 0.1  cm 1% agarose (Isogel, FMC Marine Colloids, Rockland,  ME) 
gels cast on Gel Bond (FMC Marine Colloids) using a flat bed apparatus (LKB, 
Multiphor) by the protocol described by the manufacturer.  Ampholines (Phar- 
macia  Fine  Chemicals,  LKB  Stockholm,  Sweden;  or  Separation  Sciences, 
Attleboro, MA) ranged from pH 6.5 to pH 9.0 or from pH 3 to 10. 
IODINATION OF SPECIFIC MONOCLONAL ANTIBODIES, GOAT AN- 
TIMOUSE ANTIBODIES,  AND  PROTEIN A:  DEAL-purified monoclonal 
antibodies,  affinity-purified  goat  anti-mouse  F('ab)2  (Cappel  Laboratories, 
Cochranville, PA), and Protein A (Pharmacia  Fine Chemicals) were iodinated 
with Nat2~l (-50/aCi/#l diluted from -500 uCi/#l  stock with deionized water 
just before use) using chloramine T as an oxidant (15). When iodinated proteins 
that had been chromatographed  on G-25 were precipitated with 10% ice cold 
trichloroacetic  acid, all  of the  iodine  precipitated  with  the  protein.  Specific 
activity varied from 5-50  x  10 j7 cpm/mol and the molar ratio  of iodine to 
protein varied from 0.5-2 mol/mol. Antibodies labeled in this fashion displayed 
little nonspecific binding in the solid-phase binding  assay described below: if 
wells containing  myosin-lI  were incubated  with  ~2~I-control antibody,  -0.5- 
1%  of the  total  counts were bound. Similarly, if wells plated  with  skeletal 
muscle myosin were incubated  with ~25I-myosin-II  antibodies, only 0.5-1%  of 
the counts bound.  In contrast,  15-50% of all the counts bound to myosin-lI 
coated  wells provided  that antibody  was not saturating  the  antigen  present. 
Two of 22 specific antibodies  labeled had insufficient specific activity for the 
competitive binding assays described in the methods (M2.11 and M2.19). 
SOLID-PHASE  BINDING  ASSAY:  Antibody  concentrations  in serum, 
culture  medium, ascites fluid, and purified antibody  preparations  were mea- 
sured semi-quantitatively by a modified solid-phase binding assay (44). Native 
antigen (10-1,000  ng) in 50/al of 10 mM imidazole-C1, pH 7.0, was dried onto 
the bottom of  polystyrene wells (~380 ~1, -0.32 cm  2  bottom surface area) using 
a  hair dryer.  Temperatures  in  the  bottom  of the  well reached  -45-50"C. 
Alternately 50 #1 of antigen was placed in the wells, incubated  - 15 min, then 
removed without drying. Wells stored at 4"C for up to 30 wk displayed sufficient 
binding activity for these solid-phase binding assays. Wells coated with myosin 
were rinsed once with STTAB wash solution  (see Materials and Methods) to 
minimize nonspecific binding of antibodies and protein A. Test samples of 50 
to 250 #1 containing  antibodies  (culture  medium superuatant  or dilutions  of 
antibody in STTAB) were next plated onto each well and incubated  at room 
temperature  for  1-4  h.  For each  assay, controls  included  incubation  with 
hybridoma  growth medium,  STTAB alone, or purified monoclonal  antibody 
that was previously shown not to bind to myosin-I or -II. The control antibody 
used most frequently was a  mouse monoclonal  antibody  to chicken  skeletal 
muscle myosin subfragment-1 (24). Test solutions were removed, and the plates 
were rinsed rapidly with three changes of 350 ~1 STTAB. Next, the plates were 
incubated  with 50 ~1 of STTAB containing  -50,000 cpm of ~251-1abeled goat 
antibody to mouse F(ab')2 antibody  fragments. Alternately, we incubated the FIGURE 8  SDS gel electrophoresis of monoclonal antibodies puri- 
fied from ascites fluid by DEAE chromatography. (Upper panel and 
lanes 22-27 in lower panel) Monoclonal antibodies against myosin- 
II (M2.x). (Lower panel)  Lanes 1/1, 1/4, 1/7, 1/8, I/2,  I/3,  1/5, and 
I/6  are monoclonal antibodies directed against  myosin-I.  Other 
monoclonals are directed against: AN,  an  unknown antigen; CP, 
Acanthamoeba  capping protein produced  by John Cooper, Don 
Kaiser, and Dan Kiehart; and D, chicken pectoralis myosin subfrag- 
ment-1; DY, sea urchin egg cytoplasmic dynein. Molecular weight 
markers migrate as shown in lanes marked S. Molecular weight (X 
10  -3  ) is shown to the left of each gel. 
plates with unlabeled goat antimouse antibody  (Cappel Laboratories), washed 
three times with STTAB, and incubated with -50,000 cpm of ~2~I-protein A in 
50 el of STTAB. After l-h incubation,  the plates were washed three times with 
STTAB to remove  unbound, radiolabeled antibody  or protein  A. Wells were 
removed  and counts bound were quantified  in a gamma counter.  The assay 
was reliable as a semi-quantitative  measure of antibody concentration  even if 
the time or temperature  of incubation  was varied, providing that all samples 
compared were treated in an identical fashion. 
IG  ISOTYPING:  The isotype  of each  monoclonal  antibody  was deter- 
mined by Ouchterlony  double diffusion analysis (1 l) against rabbit  Ig typing 
sera  for  mouse lgG~, lgG2A, IgO2s, IgG3, ]gM, and whole  mouse lg (Miles 
Laboratories, Elkhart,  IN). The test monoclonal  antibodies were concentrated 
approximately  20-fold from culture  medium by precipitation  with  50%  am- 
monium sulfate followed by resuspension in, and dialysis against, 0. l M sodium 
phosphate buffer, pH 8.0. 
BIOSYNTHETIC  LABELING  OF SPECIFIC  MONOCLONAL  ANTIBOD- 
IES WITH [3~S]METHIONINE:  Antibodies were labeled biosynthetically by 
growing  l07 cells overnight  in 5-l0 ml of culture  media  consisting of RPMI 
1640 without methionine,  10% NCTC (which contributes  3 pM cold methio- 
nine, -3% of its level in normal RPM! growth mediums),  50 pCi (3.5-7  pM) 
of [35S]methionine (Amersham Corp.,  Arlington  Heights, IL) and  10%  FBS 
dialyzed against  150 mM NaCl, glutamine,  HT,  and IPO (see above,  under 
fusions). Specific activities of labeled proteins  ranged from  l0 ~5 to l0 j6 cpm/ 
mol lg. Three of the 23  monoclonals  (M2.1, -21, and -27) did not label well 
enough for use in competitive binding assays. 
DETERMINATION  OF  APPARENT  BINDING  AFFINITY;  ~251-1abeled 
and 3~S-labeled antibodies were used in a solid-phase binding assay to evaluate 
the apparent Ko for each antibody binding to myosin-II. Wells containing ~200 
ng (0.5 pmol) of bound myosin-If were incubated with various concentrations 
of labeled  antibody  and  washed  as described  above.  Bound antibody  was 
measured  by counting  the  ~251 or 35S. The concentration  of 35S-antibodies in 
culture medium was estimated with a solid-phase binding assay using myosin- 
II-containing  wells, DEAL-purified, homologous  antibody as the standard, and 
J2SI-anti mouse F(ab')2 antibody to detect both the standard and the unknown 
concentration  of asS-labeled antibody. The Jss was not detected by the gamma 
counter. Backgrounds were determined as described in the competitive binding 
assays section. The Ko of  each antibody was determined from a Scatchard plot. 
The Ko, as determined  by a solid-phase binding assay, is an apparent  value 
that is theoretically  related to the amount of myosin-lI  that is bound to the 
solid-phase support (18). The apparent  KD that we measured  experimentally 
varied by a factor of 2 as the amount of antigen plated in the polystyrene wells 
varied from 0.2 to 3.2 eg (data  not shown). The apparent KD'S tabulated  are 
probably a measure of the apparent affinity of the antibodies within an order 
of magnitude  for three  reasons.  First, apparent  dissociation  constants  deter- 
mined with  125I-labeled antibodies  were all within  an order  of magnitude  of 
those  determined  with  a~S-labeled antibodies  and  second,  the  dissociation 
constant  for antibody  M2.2, determined  by two other methods (competitive 
binding and kinetic methods,  data  not shown, see reference 45  for methods) 
resulted in values within  a factor of two of those tabulated.  Finally, Kennel 
(18) characterized the apparent  Kt, of a monoclonal  antibody  against human 
fibrinogen fragment D under solution  and solid-phase conditions.  The values 
he obtained agreed within an order of magnitude. 
The wells contained  -0.5  pmol of myosin-lI  (estimated  with  ~2~l-labeled 
myosin-il, data not shown) and the abscissal intercept of  all the Scatchard plots 
showed that 0.3 to 0.6 pmol of antibody bound at saturation.  Thus the ratio of 
antibody  to myosin was about 1:1  and the antigenic sites on myosin-II were 
equally available. 
PREPARATION  OF  MYOSIN-II  PEPTIDES  BY  PROTEOLYTIC  AND 
CHEMICAL CLEAVAGE:  Fragments  of myosin-ll  were generated by three 
proteolytic and two chemical cleavage agents and then separated by gel electro- 
phoresis before transfer  to nitrocellulose paper and reaction  with the  mono- 
clonal antibodies. 
TRYPSIN:  Native myosin-II (0.47 mg in 0.4 ml) in 30% sucrose, 10 mM 
imidazole-Cl, pH 7.0 was digested for 1 min at 0*C with 4 el of 0.04 mg/ml of 
TPCK trypsin (Worthington  Biochemical Corp., Freehold,  N  J). The reaction 
was quenched  by the addition  of 7.5  el  of 0.1  mg/ml of soybean  trypsin 
inhibitor  (Worthington  Biochemical Corp.).  Gel  samples were prepared  im- 
mediately by adding  an equal  volume  of boiling SDS gel two times sample 
buffer (0.3 M Tris-Cl, pH 6.8, 30% sucrose, 4 mM EDTA, 0.02% bromophenol 
blue, 4% SDS, 10% beta-mercaptoethanol),  and boiling 3 rain. Peptides similar 
to those generated by tryptic digestion were once formed during dephosphoryl- 
ation of myosin-ll (method described in reference 25). The results of antibody 
staining of the  105,000- and 70,000-mol-wt peptides are shown in Fig. 2. 
HYDROXYLAMINE:  Myosin-lI was reduced and alkylated by the method 
described by Craven et al. (8), then cleaved with NH2OH (2). The sample was 
chromatographed  on Sephadex G-25-150 equilibrated  with 70%  formic acid. 
Fractions  in the void volume were pooled and lyophilized. Gel samples were 
prepared by boiling in Ix sample buffer. Results are shown in text Fig. 3. 
ALPHA-CHYMOTRYPSIN;  Myosin-ll  (0.5 ml of a 0.5 mg/ml solution) 
was dialyzed into 25 mM Tris-CI, pH 6.8, 2 mM K+-EDTA, then denatured 
by adding SDS to 0.1% and boiling immediately  for 3 min. The sample was 
brought to 25"C and hydrolyzed with 4 el of 0.5 mg/ml alpha-chymotrypsin 
(Worthington  Biochemical Corp.) at 25"C for 3 min. The reaction was termi- 
nated by boiling in an equal volume of two times sample buffer. 
v-8 PROTEASE;  SDS-denatured  myosin-II was hydrolyzed with 21 el of 
a  l  mg/ml solution  of V-8 protease (Worthington  Biochemical Corp.) by the 
protocol described for alpha-chymotrypsin. 
CYANOGEN  BROMIDE:  Myosin-If  was  reduced  and  alkylated  as de- 
scribed by Craven et al. (8), dialyzed into 0.1 M NI-hCOa, and lyophilized. The 
myosin (l  mg) was resuspended in  l  ml of 70%  formic acid, 25.2 el of 10% 
CNBr (wt/vol) in 70% formic acid was added and the mixture was incubated 
for 24 h at 25"C. The solution was frozen and lyophilized. The peptides were 
dissolved in boiling gel sample buffer. 
Materials 
CHEMICALS:  Reagent grade chemicals were obtained from the following 
sources. Aldrich Chemical  Co., Milwaukee, Wi: oxalacetic acid and Pristane 
(2,6,10,17-tetramethylpentadecane).  J. T. Baker Chemical Company,  Phillips- 
KIEHART  ET  AL.  MonoclonalAntibodies  1013 burg, N J: formic acid, glacial acetic acid; hydrochloric acid, lithium hydroxide, 
methanol, potassium hydroxide, sodium chloride, sodium hydroxide, sodium 
dibasic phosphate,  ammonium  carbonate, sucrose  and  trichloroacetic acid. 
British Drug House,  Poole,  England: SDS.  Eastman  Kodak Co.,  Rochester, 
NY: acrylamide, bis-acrylamide,  chloramine T, and DATD.  Fisher Scientific 
Company, Pittsburgh, PA: ammonium chloride, bromophenol blue, cyanogen 
bromide, DMSO, and polyethylene glycol 1000. Grand Island Biological Co., 
Grand Island, NY: DME,  Freund's complete and incomplete adjuvant, glum- 
mine, Medium NCTC 135, penicillin, RPMI 1640 without methionine, sodium 
pyruvate, and streptomycin. Merck and Co., Inc.,  Rahway, N J: sulfasalicylic 
acid. Sigma Chemical Co., St. Louis, MO: aminopterine, 8-azoguanine, Coo- 
massie Brilliant Blue R, EDTA, glutamic acid, hypoxanthine, hydroxylamine, 
imidazole,  insulin,  mercaptoethanol, ovalbumin (chicken egg), Sephadex G- 
25-150, sodium azide, sodium barbitol, thymidine, trizma base, and tyrosine. 
Schwarz-Mann, Orangeburg, NY:  ammonium sulfate, guanidine. Sterile Sys- 
tems, Inc., Logan, UT: HyClone fetal bovine serum. 
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